Dagfotin 50/850 & 50/1000 50 mg, 850 mg, 1000 mg FC tablets
PDF Leaflet Revision Date: Jan 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Adjunct therapy for Type 2 diabetes mellitus.
Dosage (summary)
Starting dose based on current regimen; max vildagliptin 100 mg/day.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Safety not established; contraindicated in breastfeeding.
Key Drug Interactions
- NSAIDs may increase lactic acidosis risk
- Alcohol increases risk of lactic acidosis
Contraindications
- GFR < 30 mL/min
- Hepatic impairment
- Hypersensitivity to components
- Diabetic ketoacidosis
Common side effects
- Hypoglycaemia
- Dizziness
- Nausea
- Angioedema
Counselling Points
- Take with meals to reduce GI side effects
- Monitor renal function regularly
- Avoid excessive alcohol intake
Serious warnings
- Risk of lactic acidosis
- Severe cutaneous adverse reactions
Important Disclaimer
The Dagfotin 50/850 & 50/1000 50 mg, 850 mg, 1000 mg FC tablets professional information leaflet below is the property of Hetero Drugs South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
